Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5693354 | European Journal of Obstetrics & Gynecology and Reproductive Biology | 2017 | 37 Pages |
Abstract
Based on the literature found in this systematic review, follow-up after a maximum of four courses of ulipristal acetate did not report any non-reversible (pre-)malignant lesions of the endometrium. Most studies focused on short term use of ulipristal acetate and their follow-up period was limited. Therefore, we believe more information concerning long term (intermittent) use is needed before it can be concluded that its use is completely safe.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Inge De Milliano, Dominique Van Hattum, Johannes C.F. Ket, Judith A.F. Huirne, Wouter J.K. Hehenkamp,